Cyclopentyl-coor, -c-coor Or -c-c-coor Patents (Class 560/122)
  • Patent number: 10752792
    Abstract: The present invention is a composition comprising (a) a coating base selected from a water-dispersed coating, an epoxy polymer coating, an alkyd coating, a Type I urethane coating, or an unsaturated polyester coating; and (b) a fluorinated ester compound represented by Formula (I): [AsY(CH2)x-Q-Z—(CH2)y—Rf]t??(I) where A is independently —OH, a C1-C18 alkyl, —CH2OH, —CH2COOH, or (CH2CH2O)a(CH2CH(CH3)O)bH; a and b are independently 0 to 3, where a+b is 1 to 3; s is 0 to 2; Y is a linear or branched alkylene organic group having t+s substitutions; x is 0 or 1; Q is —C(O)O— or —OC(O)—; Z is —(CH2)yS— or —(CH2CH2O)m(CH2CH(CH3)O)n—; y is 2 to 6; m and n are independently 0 to 6, where m+n is 1 to 6; Rf is a straight or branched perfluoroalkyl group of 2 to 20 carbon atoms; and t is 2 to 6, such that s+t is 2 to 6.
    Type: Grant
    Filed: February 28, 2017
    Date of Patent: August 25, 2020
    Assignee: THE CHEMOURS COMPANY FC, LLC
    Inventors: Karl Jeffery Sweetman, Roman B. Larichev
  • Patent number: 10160710
    Abstract: A synthesis method of 3,4-hexanedione comprises a step of 4-hydroxy-3-hexanonen oxidation, and in the step of 4-hydroxy-3-hexanonen oxidation, water is used as a catalyst, acetic acid is used as a cocatalyst, and ozone is used as an oxidizing agent to carry out an oxidation reaction on 4-hydroxy-3-hexanonen, and after the reaction, distillation under reduced pressure is carried out to obtain the 3,4-hexanedione. According to the synthesis method of 3,4-hexanedione in the invention, in the process of 4-hydroxy-3-hexanone oxidation, the 4-hydroxy-3-hexanone is placed in the water, the ozone is used for oxidation on the 4-hydroxy-3-hexanone, and the acetic acid is used as the cocatalyst, so that the entire oxidation reaction process is mild in conditions and simple to operate, no sewage is produced when the final product (3,4-hexanedione) is obtained, and the yield is greatly increased.
    Type: Grant
    Filed: July 31, 2018
    Date of Patent: December 25, 2018
    Assignee: HUAIYIN INSTITUTE OF TECHNOLOGY
    Inventors: Lei He, Shan Yun, Kun Hong, Tan Guo, Xiufang Zhu, Jiadong Zhang, Huaju Li, Chaoyu Wang, Jing Chen, Ying Xu
  • Publication number: 20150126744
    Abstract: This disclosure relates to new metal complexes, such as compounds of Formula 1, and their application in olefin or alkyne metathesis and to methods of carrying out olefin metathesis reactions.
    Type: Application
    Filed: December 12, 2014
    Publication date: May 7, 2015
    Inventors: Krzysztof Skowerski, Michal Bieniek
  • Publication number: 20150080577
    Abstract: The present invention relates to the cinchonidine salt useful in the preparation of intermediates for preparing a macrocyclic HCV inhibitor, as well as processes involving this salt.
    Type: Application
    Filed: November 25, 2014
    Publication date: March 19, 2015
    Inventors: Andras Horvath, Dominic John Ormerod, Dominique Paul Michel Depre, Veronique Cerpentier
  • Publication number: 20150057449
    Abstract: One embodiment of the invention provides polyisobutylene (PIB) oligormers that are end-functionalized with ruthenium (Ru) catalysts. Such nonpolar catalysts can be dissolved in nonpolar solvents such as heptane, or any other nonpolar solvent that is otherwise not latently biphasic (i.e., if two or more solvent components are present, they remain miscible with each other throughout the entire reaction process, from the addition of substrate through to the removal of product). Substrate that is dissolved in the nonpolar solvent with the catalyst is converted into product. The lower solubility of the product in the nonpolar solvent renders it easily removable, either by extraction with a more polar solvent or by applying physical means in cases where the product precipitates from the nonpolar solvent. In this manner the catalysts are recycled; since the catalysts remain in the nonpolar solvent, a new reaction can be initiated simply by dissolving fresh substrate into the nonpolar solvent.
    Type: Application
    Filed: April 24, 2014
    Publication date: February 26, 2015
    Applicant: The Texas A&M University System
    Inventors: David E. Bergbreiter, Hassan S. Bazzi, Chayanant Hongfa
  • Publication number: 20150045558
    Abstract: The invention is directed to ruthenium-based metathesis catalysts of the Hoveyda-Grubbs type. The new N-chelating diarylamino-based ruthenium catalysts described herein are stable in solid state and in solution and reveal rapid initiation behavior. Further, the corresponding N-substituted styrene precursor compounds are disclosed. The catalysts are prepared in a cross-metathesis reaction starting from N-substituted styrene precursors. The new Hoveyda-Grubbs type catalysts are suitable to catalyze ring-closing metathesis (RCM), cross metathesis (CM) and ring-opening metathesis polymerization (ROMP). Low catalyst loadings are sufficient to convert a wide range of substrates via metathesis reactions.
    Type: Application
    Filed: March 13, 2013
    Publication date: February 12, 2015
    Applicant: Umicore AG & CO. KG
    Inventors: Herbert Plenio, Lars Peeck
  • Patent number: 8940920
    Abstract: The invention relates to the method of preparation of compounds of formula I, the precursors of homocitric acid lactone and its salts, by coupling of the compounds of formula II with bromoacetic acid esters of formula III.
    Type: Grant
    Filed: June 21, 2013
    Date of Patent: January 27, 2015
    Assignee: Tallinn University of Technology
    Inventors: Margus Lopp, Anne Paju, Katharina Matkevit{hacek over (s)}
  • Publication number: 20150025077
    Abstract: This invention relates to geranylgeranyl acetone (GGA) derivatives and the use of GGA, its isomers, and GGA derivatives in methods for inhibiting neural death, increasing neural activity, increasing axon growth and cell viability, and increasing the survival rate of subjects administered the GGA or GGA derivatives.
    Type: Application
    Filed: February 27, 2013
    Publication date: January 22, 2015
    Applicant: COYOTE PHARMACEUTICALS, INC.
    Inventors: Hiroaki Serizawa, Ankush B. Argade, Akash Datwani, Natalie Spencer, Yonghua Pan, Florian Ermini
  • Patent number: 8927722
    Abstract: The present invention relates to the cinchonidine salt useful in the preparation of intermediates for preparing a macrocyclic HCV inhibitor, as well as processes involving this salt.
    Type: Grant
    Filed: December 22, 2009
    Date of Patent: January 6, 2015
    Assignee: Janssen Pharmaceutica N.V.
    Inventors: Andras Horvath, Dominic John Ormerod, Dominique Paul Michel Depre, Veronique Cerpentier
  • Publication number: 20150005363
    Abstract: The present invention relates to a cationic lipid of formula (I) having one or more biodegradable groups located in a lipidic moiety (e.g., a hydrophobic chain) of the cationic lipid. These cationic lipids may be incorporated into a lipid particle for delivering an active agent, such as a nucleic acid. The invention also relates to lipid particles comprising a neutral lipid, a lipid capable of reducing aggregation, a cationic lipid of the present invention, and optionally, a sterol. The lipid particle may further include a therapeutic agent such as a nucleic acid.
    Type: Application
    Filed: December 7, 2012
    Publication date: January 1, 2015
    Inventors: Steven M Ansell, Xinyao Du
  • Publication number: 20140378698
    Abstract: The invention relates to the method of preparation of compounds of formula I, the precursors of homocitric acid lactone and its salts, by coupling of the compounds of formula II with bromoacetic acid esters of formula III.
    Type: Application
    Filed: June 21, 2013
    Publication date: December 25, 2014
    Inventors: Margus LOPP, Anne PAJU, Katharina MATKEVITÅ MATKEVITÅ
  • Publication number: 20140350241
    Abstract: Provided herein are ruthenium complexes of Formula I, and processes of preparation thereof. Also provided are methods of their use as a metathesis catalyst.
    Type: Application
    Filed: June 6, 2014
    Publication date: November 27, 2014
    Inventors: Christophe Claude PARSY, Francois-Rene ALEXANDRE, Florence Marie-Emilie BONNATERRE, Dominique SURLERAUX
  • Patent number: 8895040
    Abstract: The present invention relates to cosmetic and/or personal care formulations and/or compounds. In one embodiment, the present invention relates to ester compounds that can be used in various personal care formulations and/or compounds. In another embodiment, the present invention relates to branced ester compounds having a molecular weight of at least about 1,500 daltons that can be used in various personal care formulations and/or compounds.
    Type: Grant
    Filed: June 4, 2009
    Date of Patent: November 25, 2014
    Assignee: Lubrizol Advanced Materials, Inc.
    Inventors: Brian J. Vondruska, Peter Frank, Anchuu Wu
  • Publication number: 20140330018
    Abstract: The present application provides, among other things, novel compounds and methods for metathesis reactions. In some embodiments, a provided compound has the structure of formula I. In some embodiments, the present invention provides methods for preparing a compound of formula I. In some embodiments, the present invention provides metathesis methods comprising providing a compound of formula I.
    Type: Application
    Filed: May 1, 2014
    Publication date: November 6, 2014
    Applicants: Massachusetts Institute of Technology, Ximo AG
    Inventors: Janos Czirok, Georg Frater, Levente Ondi, Richard Royce Schrock, Florian Toth
  • Patent number: 8871879
    Abstract: The invention provides novel organometallic complexes useful as olefin metathesis catalysts. The complexes have an N-heterocyclic carbene ligand and a chelating carbene ligand associated with a Group 8 transition metal center. The molecular structure of the complexes can be altered so as to provide a substantial latency period. The complexes are particularly useful in catalyzing ring closing metathesis of acyclic olefins and ring opening metathesis polymerization of cyclic olefins.
    Type: Grant
    Filed: February 27, 2013
    Date of Patent: October 28, 2014
    Assignees: Materia, Inc., California Institute of Technology
    Inventors: Thay Ung, Yann Schrodi, Mark S. Trimmer, Andrew Hejl, Daniel Sanders, Robert H. Grubbs
  • Publication number: 20140296516
    Abstract: The invention relates to metal complexes of general formula (I) and to a method for the production thereof, in which M, R1, R2, R3, X and Y in addition to Ra, Rb, Rc, Rd, Re, Rf, Rg, Rh can have the meanings defined in the claims. Said metal complexes form air-stable compounds and are suitable as pre-catalysts in the olefin metathesis.
    Type: Application
    Filed: February 23, 2012
    Publication date: October 2, 2014
    Applicant: STUDIENGESELLSCHAFT KOHLE MBH
    Inventors: Alois Furstner, Johannes Heppekausen
  • Patent number: 8835628
    Abstract: The present invention relates to catalytically active compounds of the general formula (1) that are highly tunable, as well as to a method of their preparation and their use in any type metathesis reaction. The new compounds of the present invention comprise activation sites that allow for specific catalyst design. Particularly, side chains and ligands allow efficient activity and specificity control of the catalysts of the present invention.
    Type: Grant
    Filed: July 30, 2010
    Date of Patent: September 16, 2014
    Assignees: Ecole Nationale Superieure de Chimie de Rennes, Centre National de la Recherche Scientifique CNRS
    Inventors: Marc Mauduit, Frédéric Caijo, Christophe Crevisy
  • Patent number: 8828967
    Abstract: New low molecular weight complexes between iron and maltobionic acid that can be administered parenterally, preferably intramuscularly or subcutaneously, in the treatment of anemic states, caused by iron deficiencies, and new pharmaceutical compositions adapted for this use. In particular, the invention provides a new complex between preferably trivalent iron and maltobionic acid that is characterized by a molecular weight Mw between 10,000 and 30,000 Da, by a polydispersity of 1.0-1.8 and by an iron content between 25% and 40% by weight.
    Type: Grant
    Filed: June 8, 2011
    Date of Patent: September 9, 2014
    Assignee: Biofer S.p.A.
    Inventors: Michele Autuori, Dario Bosi, Alessandro Lapini Sacchetti, Egidio Marchi
  • Patent number: 8822507
    Abstract: The present invention pertains generally to the field of therapeutic compounds, and more specifically to certain aryl-phenyl-sulfonamido-cycloalkyl compounds of the following formula (collectively referred to herein as “APSAC compounds”).
    Type: Grant
    Filed: May 3, 2013
    Date of Patent: September 2, 2014
    Assignee: PIMCO 2664 Limited
    Inventors: Iain Robert Greig, Rose Mary Sheridan, Raymond Fisher, Matthew John Tozer, Juha Andrew Clase, Andrew Smith, Andrew Robert Tuffnell, Robert Jurgen Van 't Hof
  • Publication number: 20140228563
    Abstract: Cis and trans ruthenium complexes that can be used as catalysts for ring opening metathesis polymerisation (ROMP) are described. The complexes are generally square pyramidal in nature, having two anionic ligands X. Corresponding cationic complexes where one or both of the anionic ligands X are replaced by a non-co-ordinating anionic ligand are also described. Polymers such as polydicyclopentadiene (PDCPD) can be prepared using the catalysts.
    Type: Application
    Filed: September 28, 2012
    Publication date: August 14, 2014
    Applicant: University Court of the University of St. Andrews
    Inventor: Catherine Cazin
  • Publication number: 20140228574
    Abstract: Disclosed is a process for the preparation of a cinchonidine salt of formula (IV) via an aqueous solution of a racemic 4-hydroxy-1,2-cyclopentanedicarboxylic acid, which is subjected to cyclization without removing water, by the addition of a water-miscible organic solvent to the aqueous solution and, again without removing water, adding cinchonidine to the aqueous-organic solvent solution so as to obtain the cinchonidine salt of the lactone acid. The cinchonidine salt is allowd to crystallize so as to obtain the enantiomerically purified crystalline lactone acid cinchonidine salt (IV). The enantiomerically pure salt is an intermediate in the synthesis of HCV inhibitor compound of formula (I).
    Type: Application
    Filed: September 21, 2012
    Publication date: August 14, 2014
    Inventors: Andras Horvath, Dominique Paul Michel Depré, Dominic John Ormerod
  • Publication number: 20140220122
    Abstract: The invention relates to methods, compounds, compositions and vehicles for delivering 3-amino-1-propanesulfonic acid (3APS) in a subject, preferably a human subject. The invention encompasses compound that will yield or generate 3APS, either in vitro or in vivo.
    Type: Application
    Filed: April 7, 2014
    Publication date: August 7, 2014
    Applicant: BHI Limited Partnership
    Inventors: Xianqi KONG, Mohamed ATFANI, Benoit BACHAND, Abderrahim BOUZIDE, Stephane CIBLAT, Sophie LEVESQUE, David MIGNEAULT, Isabelle VALADE, Xinfu WU, Daniel DELORME
  • Publication number: 20140194505
    Abstract: Disclosed are neuraminidase inhibitor compounds and pharmaceutical compositions with improved bioavailability and/or improved efficacy and methods of treating influenza using the compounds and pharmaceuticals compositions.
    Type: Application
    Filed: February 11, 2014
    Publication date: July 10, 2014
    Applicant: SineVir Therapeutics LLC
    Inventors: John Hilfinger, Wei Shen
  • Publication number: 20140187617
    Abstract: Provided are compounds that are inhibitors of both rho kinase and of a monoamine transporter (MAT) act to improve the disease state or condition. Further provided are compositions comprising the compounds. Further provided are methods for treating diseases or conditions, the methods comprising administering compounds according to the invention. One such disease may be glaucoma for which, among other beneficial effects, a marked reduction in intraocular pressure (IOP) may be achieved.
    Type: Application
    Filed: December 23, 2013
    Publication date: July 3, 2014
    Applicant: AERIE PHARMACEUTICALS, INC.
    Inventors: Mitchell A. deLong, Jill Marie Sturdivant, Susan M. Royalty
  • Publication number: 20140171607
    Abstract: The present invention provides new ruthenium complexes of Formula (1), which contain a chelate ring created by a halogen atom X. The invention concerns also a method for the preparation of the new ruthenium complexes and their application in metathesis reactions.
    Type: Application
    Filed: June 4, 2012
    Publication date: June 19, 2014
    Applicant: UMICORE AG & CO. KG
    Inventors: Karol Grela, Michal Barbasiewicz, Michal Michalak
  • Publication number: 20140155511
    Abstract: Sulfur chelated ruthenium compounds represented by the following formula: wherein M indicates the ruthenium metal bound to a benzylidene carbon; R represents C1-C7 alkyl group or optionally substituted aryl; X1 and X2 each independently represent halogen; Y1 and Y2 each independently denote unsubstituted or alkyl-substituted phenyl; and Z independently represents hydrogen, electron withdrawing or electron donating substituent, with m being an integer from 1 to 4, and processes and compositions related thereto.
    Type: Application
    Filed: July 18, 2013
    Publication date: June 5, 2014
    Inventors: N. Gabriel LEMCOFF, Amos BEN-ASULY
  • Publication number: 20140114027
    Abstract: A cage 1,2,3,4-cyclopentanetetracarboxylic acid (1,3:2,4)-dianhydride compound represented by formula [1], and a polyimide obtained by condensing the compound with a diamine. With the compound, it is possible to provide a polyimide which shows no absorption in the ultraviolet region and is highly transparent to light, has high insulating properties, has improved heat resistance and processability, and has excellent solubility in organic solvents. (In formula [1], R1 and R2 each independently represents a hydrogen atom, a halogen atom, or a C1-10 alkyl.
    Type: Application
    Filed: December 31, 2013
    Publication date: April 24, 2014
    Applicant: NISSAN CHEMICAL INDUSTRIES, LTD.
    Inventors: Hideo Suzuki, Takahiro Noda
  • Publication number: 20140005408
    Abstract: This disclosure relates to new metal complexes, such as compounds of Formula 1, and their application in olefin or alkyne metathesis and to methods of carrying out olefin metathesis reactions.
    Type: Application
    Filed: June 18, 2013
    Publication date: January 2, 2014
    Applicant: APEIRON SYNTHESIS S.A.
    Inventors: Krzysztof Skowerski, Michal Bieniek
  • Publication number: 20130338370
    Abstract: The invention is directed to aryl alkylidene ruthenium complexes and the use of these complexes as catalysts in metathesis reactions.
    Type: Application
    Filed: August 5, 2013
    Publication date: December 19, 2013
    Applicant: Evonik Degussa GmbH
    Inventors: Renat Kadyrov, Anna Rosiak
  • Publication number: 20130331446
    Abstract: The invention relates to compounds of general formula I, (I), wherein R is wherein R is aryl substituted by R3; or R is (C3-Ci3)-cycloalkyl, (C3-Ci3)-cycloalkenyl or (C7-Ci3)-cycloalkynyl optionally substituted by R4; and pharmaceutically acceptable salts, hydrates, or solvates thereof, for use—alone or in combination with one or more other pharmaceutically active compounds—in therapy, for preventing, treating or ameliorating diseases or conditions responsive to stimulation of neutrophil oxidative burst, responsive to stimulation of keratinocyte IL-8 release or responsive to induction of necrosis.
    Type: Application
    Filed: December 22, 2011
    Publication date: December 12, 2013
    Applicant: LEO LABORATORIES LIMITED
    Inventors: Gunnar Grue-Sørensen, Xifu Liang, Thomas Högberg, Kristoffer Månsson, Per Vedsø
  • Publication number: 20130296323
    Abstract: This invention relates to geranylgeranyl acetone (GGA) derivatives and the use of GGA, its isomers, and GGA derivatives in methods for inhibiting neural death, increasing neural activity, increasing axon growth and cell viability, and increasing the survival rate of subjects administered the GGA or GGA derivatives.
    Type: Application
    Filed: February 27, 2013
    Publication date: November 7, 2013
    Applicant: COYOTE PHARMACEUTICALS, INC.
    Inventors: Hiroaki Serizawa, Ankush B. Argade, Akash Datwani, Natalie Spencer, Yonghua Pan, Florian Ermini
  • Publication number: 20130296511
    Abstract: The invention provides novel organometallic complexes useful as olefin metathesis catalysts. The complexes have an N-heterocyclic carbene ligand and a chelating carbene ligand associated with a Group 8 transition metal center. The molecular structure of the complexes can be altered so as to provide a substantial latency period. The complexes are particularly useful in catalyzing ring closing metathesis of acyclic olefins and ring opening metathesis polymerization of cyclic olefins.
    Type: Application
    Filed: February 27, 2013
    Publication date: November 7, 2013
    Inventors: Thay UNG, Yann SCHRODI, Mark S. TRIMMER, Andrew HEJL, Daniel SANDERS, Robert H. GRUBBS
  • Publication number: 20130288179
    Abstract: A radiation-sensitive resin composition includes a compound represented by a formula (1), and a polymer that includes a structural unit having an acid-labile group. R1 and R4 each independently represent a hydrogen atom, or the like. R2 and R3 each independently represent a hydrogen atom or the like. X1 and X2 each independently represent a hydrogen atom, or the like, or X1 and X2 taken together represent —S—, —O—, —SO2—, or the like. A represents an ethanediyl group, wherein at least one hydrogen atom included in X1, X2 and A is substituted by —Y—SO3?M+. Y represents an alkanediyl group having 1 to 10 carbon atoms, or the like. M+ represents a monovalent onium cation. In the case where —Y—SO3?M+ is present in a plurality of number, a plurality of Ys are each identical or different and a plurality of M+s are each identical or different.
    Type: Application
    Filed: June 27, 2013
    Publication date: October 31, 2013
    Inventors: Kazuo NAKAHARA, Ken MARUYAMA
  • Publication number: 20130267698
    Abstract: Provided herein are ruthenium complexes of Formula I, and processes of preparation thereof. Also provided are methods of their use as a metathesis catalyst.
    Type: Application
    Filed: June 5, 2013
    Publication date: October 10, 2013
    Inventors: Christophe Claude Parsy, Francois-Rene Alexandre, Florence Marie-Emilie Bonnaterre, Dominique Surleraux
  • Publication number: 20130261296
    Abstract: Catalytic complexes including a metal atom having anionic ligands, at least one nucleophilic carbene ligand, and an alkylidene, vinylidene, or allenylidene ligand. The complexes are highly stable to air, moisture and thermal degradation. The complexes are designed to efficiently carry out a variety of olefin metathesis reactions.
    Type: Application
    Filed: January 25, 2013
    Publication date: October 3, 2013
    Inventors: Steven P. NOLAN, Jinkun HUANG
  • Publication number: 20130245018
    Abstract: The present invention pertains generally to the field of therapeutic compounds, and more specifically to certain aryl-phenyl-sulfonamido-cycloalkyl compounds of the following formula (collectively referred to herein as “APSAC compounds”).
    Type: Application
    Filed: May 3, 2013
    Publication date: September 19, 2013
    Applicant: PIMCO 2664 LIMITED
    Inventors: Iain Robert Greig, Rose Mary Sheridan, Raymond Fisher, Matthew John Tozer, Juha Andrew Clase, Andrew Smith, Andrew Robert Tuffnell, Robert Jurgen Van 't Hof
  • Publication number: 20130211096
    Abstract: There is disclosed compounds of formula 1, their preparation, intermediates for the preparation and the use of the compounds of the formula 1 as catalysts in various metathesis reactions. The novel metathesis catalysts, which are obtained from readily available precursors, have a high activity and can be used for any type of metathesis reaction.
    Type: Application
    Filed: September 10, 2012
    Publication date: August 15, 2013
    Inventors: Dieter Arlt, Michal Bieniek, Ralf Karch
  • Publication number: 20130197218
    Abstract: The present invention relates to catalytically active compounds of the general formula (1) that are highly tunable, as well as to a method of their preparation and their use in any type metathesis reaction. The new compounds of the present invention comprise activation sites that allow for specific catalyst design. Particularly, side chains and ligands allow efficient activity and specificity control of the catalysts of the present invention.
    Type: Application
    Filed: July 30, 2010
    Publication date: August 1, 2013
    Inventors: Marc Mauduit, Frédéric Caijo, Christophe Crevisy
  • Publication number: 20130165649
    Abstract: Cls ruthenium complexes that can be used as catalysts are described. The complexes are generally square pyramidal in nature, having two anionic ligands X adjacent to each other. The complexes can be used as catalysts, for example in olefin metathesis reactions. Corresponding trans ruthenium complexes are also described, together with cationic complexes where one or both of the anionic ligands X are replaced by a non-co-ordinating anionic ligand.
    Type: Application
    Filed: March 21, 2011
    Publication date: June 27, 2013
    Inventor: Catherine Cazin
  • Publication number: 20130150572
    Abstract: Provided herein are ruthenium complexes of Formula I, and processes of preparation thereof. Also provided are methods of their use as a metathesis catalyst.
    Type: Application
    Filed: February 12, 2013
    Publication date: June 13, 2013
    Applicant: IDENIX PHARMACEUTICALS, INC.
    Inventor: Idenix Pharmaceuticals, Inc.
  • Publication number: 20130085283
    Abstract: Provided herein are geranylgeranylacetone derivatives and methods of using them.
    Type: Application
    Filed: March 1, 2012
    Publication date: April 4, 2013
    Inventors: Hiroaki Serizawa, Ankush B. Argade, Akash Datwani, Natalie Spencer
  • Patent number: 8394994
    Abstract: The present invention relates to [1] a process for producing a 2-alkyl-2-cycloalken-1-one represented by the following general formula (2), which includes the step of subjecting a 2-(1-hydroxyalkyl)cycloalkan-1-one to dehydration and isomerization in the co-existence of an acid and a platinum group metal catalyst, and [2] a process for producing an alkyl(3-oxo-alkylcycloalkyl)acetate which is useful as a perfume material, using the 2-alkyl-2-cycloalken-1-one: wherein n is an integer of 1 or 2; and R1 and R2 are each independently a hydrogen atom or an alkyl group having 1 to 8 carbon atoms with the proviso that R1 and R2 may form a ring through a carbon atom adjacent thereto.
    Type: Grant
    Filed: April 2, 2009
    Date of Patent: March 12, 2013
    Assignee: Kao Corporation
    Inventors: Makiko Muroi, Atsushi Nagasawa, Kunshi Matsumoto, Mariko Kagaya, Hirotsugu Nishimura, Yoshiharu Ataka
  • Publication number: 20130060028
    Abstract: This invention relates to methods of making a compound of formula (I) and intermediates for same the compounds of formula (I) being useful for treating cardiovascular and inflammatory diseases such as atherosclerosis.
    Type: Application
    Filed: May 17, 2011
    Publication date: March 7, 2013
    Inventors: Kevin Stuart Cardwell, Claire Frances Crawford, Suzanne Helen Davies, Charles Edward Wade
  • Publication number: 20130035322
    Abstract: Gold (I) hydroxide complexes of the form Z-Au-OH and digold complexes of the form Z—Au-(?OH)—Au—Z where groups Z are two electron donors are provided. The groups Z may be carbenes, for example nitrogen containing heterocyclic carbenes (NHCs), phosphines or phosphites. The complexes can be used as catalysts, for example in reactions such as hydration of nitriles, skeletal arrangement of enynes, alkoxycyclisation of enynes, alkyne hydration, the Meyer-Shuster reaction, 3,3? rearrangement of allylic acetates, cyclisation of propargylic acetates, Beckman rearrangements and hydroamination. The complexes can be used in medicine, for example in the treatment of cancer.
    Type: Application
    Filed: March 2, 2011
    Publication date: February 7, 2013
    Applicant: University Court of The University of St. Andrews
    Inventor: Steven P. Nolan
  • Publication number: 20130023585
    Abstract: Disclosed are neuraminidase inhibitor compounds and pharmaceutical compositions with improved bioavailability and/or improved efficacy and methods of treating influenza using the compounds and pharmaceuticals compositions.
    Type: Application
    Filed: April 4, 2011
    Publication date: January 24, 2013
    Applicant: TSRL, INC.
    Inventors: John Hilfinger, Wei Shen
  • Patent number: 8324331
    Abstract: A compound represented by general formula (a-i) below, and a polymeric compound having a structural unit represented by general formula (a-ii) below (wherein R represents a hydrogen atom, a lower alkyl group or a halogenated lower alkyl group; X represents a divalent organic group represented by general formula (x-1) below; and R1 represents an organic group having a fluorine atom).
    Type: Grant
    Filed: December 16, 2009
    Date of Patent: December 4, 2012
    Assignee: Daito Chemix Corporation
    Inventors: Toshiharu Shimamaki, Kenji Uenaga
  • Patent number: 8278477
    Abstract: The method for making a phosphorus ylide produces the ylide 2,3-bismethoxycarbonyl-4-phenyl-5-arylhydrazono-cyclopenta-1,3-dienyl-triphenylphosphonium in pure form by simple recrystallization of the reaction product. 3-Oxo-3-phenyl-2-(arylhydrozono)propanal and dimethylacetylenedicarboxylate are mixed in dichloromethane at room temperature. After cyclization of the intermediate (preferably at least two hours), triphenylphosphine is added to the mixture, ultimately resulting in formation of 2,3-bismethoxycarbonyl-4-phenyl-5-arylhydrazono-cyclopenta-1,3-dienyl-triphenylphosphonium. The product is recrystallized to produce 2,3-bismethoxycarbonyl-4-phenyl-5-arylhydrazono-cyclopenta-1,3-dienyl-triphenylphosphonium in pure form and in high yield. The aryl group may be any aromatic or aliphatic group.
    Type: Grant
    Filed: December 22, 2009
    Date of Patent: October 2, 2012
    Assignee: King Abdulaziz University
    Inventor: Khadijah M. Al-Zaydi
  • Patent number: 8252788
    Abstract: Compounds comprising or a pharmaceutically acceptable salt or a prodrug thereof are disclosed, wherein a dashed line represents the presence or absence of a bond; and, wherein Y, A, R, D, and n are as described. Methods, compositions, and medicaments related thereto are also disclosed.
    Type: Grant
    Filed: May 13, 2009
    Date of Patent: August 28, 2012
    Assignee: Allergan, Inc.
    Inventors: David W. Old, Vinh X. Ngo
  • Publication number: 20120135984
    Abstract: Provided are compounds, compositions, and methods for treating diseases and conditions wherein an inhibitor of a kinase, such as rho kinase (ROCK), and an inhibitor of one or more of the monoamine transporters, such as NET or SERT, act in concert to improve the condition.
    Type: Application
    Filed: May 1, 2010
    Publication date: May 31, 2012
    Inventors: Mitchell A. deLong, Jill Marie Sturdivant, Susan M. Royalty, Geoffrey Richard Heintzelman, Jeffrey D. Yingling, Casey Kopczynski
  • Publication number: 20120131700
    Abstract: The invention provides seed treatment compositions as well as their use, methods for treating seeds, methods of protecting plants against pests and also treated seeds and plants. In one embodiment there is provided a method of treating a seed with a seed treatment composition to induce a plant resistance mechanism against one or more pests in a plant grown from said seed.
    Type: Application
    Filed: January 12, 2012
    Publication date: May 24, 2012
    Applicant: Plant Bioscience Limited
    Inventors: Michael Richard Roberts, Nigel Duncan Paul, Jane Elizabeth Taylor, Patricia Croft, Jason Paul Moore